Baird analyst David Rescott initiated coverage of TransMedics with an Outperform rating and $200 price target. TransMedics has experienced a significant revenue inflection as the company’s proprietary OCS technology has helped alleviate U.S. organ donor-transplant mismatch, says the analyst, who sees the company as “still in the early innings of capturing share and driving further market expansion.” The firm has “high conviction in best-in-class revenue growth upside” and an improving profit outlook, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- AmEx downgraded, Texas Instruments upgraded: Wall Street’s top analyst calls
- TransMedics initiated with a Buy at Needham
- TransMedics topped ‘ambitious buyside expectations,’ says Morgan Stanley
- TransMedics price target raised to $169 from $117 at Canaccord
- TransMedics price target raised to $200 from $125 at Oppenheimer